Waldenstrom Macroglobulinemia

This is a type of cancer that starts in the blood cells, specifically B-lymphocytes. It causes the body to make too much of a specific type of antibody called IgM. This can lead to anemia and bleeding problems.

Condition

What people with Waldenstrom Macroglobulinemia report

Every report comes from a Lived member, sent anonymously.

Have you tried Rituximab for Waldenstrom Macroglobulinemia?

NameHow it went

About Waldenstrom Macroglobulinemia

What It Is

Waldenstrom macroglobulinemia (WM) is a rare, slow-growing blood cancer. It is a type of non-Hodgkin lymphoma that starts in B cells, the immune cells that normally mature into antibody-making plasma cells. In WM, abnormal B cells (called lymphoplasmacytic cells) build up in the bone marrow and make large amounts of a single antibody called immunoglobulin M, or IgM. The name comes from this oversized protein, a macroglobulin. Many of the problems WM causes come from one of two things. Cancer cells crowding the bone marrow can lower blood counts, causing anemia and tiredness. The excess IgM can make the blood thicker than normal, damage nerves (often as painless numbness in the feet and legs) or cause bleeding and vision problems. Some people also have swollen lymph nodes, an enlarged spleen or liver, fevers, night sweats or weight loss. Others have no symptoms at all, and WM is found by chance on routine blood work.

Causes & Risk Factors

The cause of WM is not fully understood. The cancer cells almost always carry acquired gene changes, meaning changes that arise during life rather than being inherited. A change in a gene called MYD88 is found in more than 9 in 10 people with WM, and a change in CXCR4 in about 1 in 3. These changes help the abnormal cells survive, and they also guide treatment choices. WM is most common in older adults (the average age at diagnosis is about 70), in men and in White people. About 1 in 5 people with WM has a close relative with WM or a related B-cell disorder, so family history raises risk, though most relatives never develop it. A precursor condition called IgM MGUS (monoclonal gammopathy of undetermined significance), in which a small amount of the same abnormal IgM is present without cancer, carries a risk of about 1% to 2% a year of progressing to WM or a related disease. Some studies link WM to chronic hepatitis C, certain autoimmune diseases and farming or pesticide exposure, but these associations are uncertain and do not explain most cases.

How It's Diagnosed

WM is usually suspected from blood tests: low blood counts, a high total protein level, or a high IgM level. Serum protein electrophoresis (SPEP) and a follow-up test called immunofixation then show whether the extra protein is a monoclonal IgM, meaning many copies of one identical antibody. This abnormal protein is often called an M protein or M spike, and its level is tracked over time. A bone marrow biopsy, usually taken from the back of the hip bone under local numbing, confirms the diagnosis. WM is diagnosed when the marrow contains at least 10% lymphoplasmacytic cells along with a monoclonal IgM in the blood. The sample is also tested for MYD88 and CXCR4 changes. Other tests check for complications: blood viscosity (thickness) when IgM is high or symptoms suggest it, kidney and liver function, and sometimes computed tomography (CT) scans to look at lymph nodes and the spleen. Age and blood tests such as beta-2 microglobulin and albumin are among the factors combined into risk scores that help estimate outlook, although they cannot predict any one person's course.

Treatment Options

Not everyone with WM needs treatment right away. If WM causes no meaningful symptoms or blood count problems, the usual approach is watchful waiting: regular checkups and blood tests, with treatment started if problems appear. Treatment is recommended for anemia or other low counts, fevers, night sweats or weight loss, thick blood, nerve damage, bulky lymph nodes or an enlarged spleen, and complications of the abnormal protein, such as amyloidosis, in which part of the IgM builds up in organs like the heart and kidneys. There is no single standard first treatment, and the choice depends on age, other health problems, symptoms and the MYD88 and CXCR4 results. One main option is chemoimmunotherapy, such as bendamustine (a chemotherapy drug) combined with rituximab (an antibody that targets B cells). It is given as a set number of infusions, then stopped. The other main option is a Bruton tyrosine kinase (BTK) inhibitor, a daily pill that blocks a signal WM cells depend on, such as zanubrutinib (Brukinsa) or ibrutinib (Imbruvica). BTK inhibitors avoid chemotherapy but are taken continuously for as long as they work, and they can raise the risk of bleeding, infections and heart rhythm problems such as atrial fibrillation. Most people's disease responds within a few months, with IgM falling and symptoms easing. When IgM makes the blood too thick, plasmapheresis (plasma exchange) uses a machine to filter IgM out of the blood over a few hours. It works quickly but does not treat the cancer, so it is followed by other therapy. Rituximab can briefly push IgM even higher, so when IgM is very high doctors may lower it first. If WM returns, the same treatment may work again if the first response lasted well, or a different drug, such as another BTK inhibitor, a proteasome inhibitor or venetoclax, may be used. Stem cell transplant and clinical trials are options in selected situations.

What to Expect

WM is usually a long-term condition rather than a curable one, but many people live with it for many years, and many eventually die of unrelated causes. Some people are monitored for years before needing any treatment. For those who are treated, the pattern is often one of control followed later by return, with more than one course of treatment over a lifetime. Outlook varies widely with age, overall health and risk factors at diagnosis. Daily life depends largely on which treatment is used. Chemoimmunotherapy involves a defined stretch of infusions, tiredness and lowered blood counts, followed by a break from treatment. A BTK inhibitor means a daily pill and ongoing monitoring of blood counts, blood pressure and heart rhythm. Either way, regular blood tests track IgM and blood counts, and visits watch for nerve symptoms, infections and enlarging nodes. Infections are a common concern because both WM and its treatment can weaken the immune system. Rarely, WM transforms into a faster-growing lymphoma, which shows up as rapidly enlarging nodes, new fevers or sharply worsening health and needs different treatment.

When to Seek Help

See a doctor if you have tiredness that doesn't improve, unexplained weight loss, drenching night sweats, or new numbness or tingling in the feet, or if routine blood work shows anemia or a high protein level. If you already have WM, tell your care team about new swollen lymph nodes, a growing sense of fullness in your belly or worsening fatigue. Contact your care team right away for a fever, especially during treatment, because infections can become serious quickly. Call promptly as well for new or worsening headaches, blurred vision or blind spots, or nosebleeds or bleeding gums that won't stop, since these can be early signs that the blood has become too thick. Sudden weakness or numbness on one side, confusion, trouble speaking, a seizure or sudden loss of vision needs emergency care: call 911. In WM, very thick blood can reduce blood flow to the brain and cause stroke-like symptoms that need urgent treatment.

Questions to Ask Your Doctor

  1. 1.Does my WM need treatment now, and what changes would tell us it's time to start?
  2. 2.How do my MYD88 and CXCR4 results affect which treatment you would recommend?
  3. 3.What are the trade-offs for me between a fixed course of chemoimmunotherapy and a daily BTK inhibitor?
  4. 4.How high is my IgM, and should my blood thickness be checked?
  5. 5.How often will I need blood tests and visits, and what can I do to lower my risk of infection?

Last reviewed • Oct 2026

Educational content, not medical advice.